Clinical Trial Manager
I originally trained as a Biochemist, and have been working in healthcare research since 1999. Initially I worked as a research assistant in the Diabetes Trials Unit in Oxford. After completing a DPhil in Immunology, investigating the Varicella Zoster Virus. I moved back into clinical trials.
I joined the Department on 2010 as a Clinical Trial Co-ordinator, initially working on the MAC trial, investigating the use of Montelukast in post-infectious cough in adults, and the CAPS study, looking at the epidemiology of persistent cough in children.
As a Trial Manager i have worked on many trials such as: EDGE - investigating self-monitoring in people with COPD, MASTERMIND - investigating how people responded to different diabetes medication and their medication adherence, BARACK-D - nvestigating the use of Spironolactone in patients with Chronic Kidney Disease and FORM2C - investigating the optimal frequency of testing, and the use of different tests to monitor kidney function.
I have also been involved in various stages of a number of other trials including, POC HbA1c, CANDID, TasminH4, and StAR-2D.
I am currently the Trial and Programme manager for SuMMiT-D - investigating the use of text messages to support people with management of Type 2 Diabetes.
I am a member of the UK Trial Managers Network and for since2015 I have taught clinical trial management for the University of Oxford as a lecturer and facilitator on the Clinical Trials Management module.
Farmer A. et al, (2022), JMIR Research Protocols, 11
Farmer A. et al, (2021)
Perera R. et al, (2021), Programme Grants for Applied Research, 9, 1 - 218
FORM-2C (Frequency of Renal Monitoring – Creatinine and Cystatin C): an observational cohort study of primary care patients with reduced eGFR
Fleming S. et al, (2021), British Journal of General Practice
On-site monitoring of primary outcomes is important in primary care clinical trials: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK-D) Trial a case study
Jones L. et al, (2019), TRIALS, 20